To establish the mechanism of action (MOA) by which exarafenib could exert anti-tumor effects in human cancer cells, we conducted a series of experiments using patient-derived lung cancer cell lines harboring BRAF mutations (Fig. 2b). The gene discussed is BRAF; the disease is lung carcinoma.